Study of the relationship between the serum YKL 40 levels and pathological grade and prognosis of glioma

Yang Shuai; Wang Weimin; Zhang Xiaopeng; Liu Yibing

doi:10.11850/j.issn.1009-122X.2014.10.002

Abstract：Objective To investigate the relationship between the serum YKL-40 levels and pathological grade and prognosis of glioma. Methods The serum YKL-40 level was detected by enzyme-linked immunosorbent assay (ELISA) in 68 cases of glioma (glioma group) and 20 healthy subjects (control group). Of the 68 cases, 2 were in pathological gradeⅠ, 17 in gradeⅡ, 15 in grade Ⅲ, and 34 in gradeⅣ. The survival time was <12 months in 15 cases, 12-24 months in 15 and >24 months in 38. Before recurrence, 10 patients died, the recurrence time was <12 months in 14 cases, 12-24 months in 15 and >24 months in 29. Results There was no significant difference in serum YKL-40 levels between the low-class (grade Ⅰ-Ⅱ) patients and control group (P >0.05). Meanwhile, the serum YKL-40 level in class Ⅳ patients was significantly higher than that in the others (P <0.05). Besides, YKL-40 levels in the patients whose survival time was less than 12 months or from 12 to 24 months were significantly higher than those in the patients whose survival time was longer than 24 months (P <0.05). YKL-40 levels in relapsed patients, especially in the patients relapsed in 12 months, were higher than those in the patients without recurrence (P <0.05). The recurrence time was also significantly longer in the patients relapsed in 12 months than in the patients relapsed during 12 to 24 months (P <0.05). Conclusions Serum YKL-40 level is related to the pathological grade and prognosis of glioma, and can be considered as the indicators for judging the malignancy grade and prognosis.